Target Audience and Goal Statement

This educational activity is intended for an audience of oncologists, gastroenterologists, surgeons, and other clinicians on the multidisciplinary team in the United States.

The goal of this activity is for learners to be better able to incorporate immunotherapy strategies into the management of patients with HCC.

Upon completion of this activity, participants will:

• Have increased knowledge regarding the clinical trial data associated with immunotherapy-based strategies for frontline treatment of advanced unresectable HCC.
• Have greater competence related to selecting the most appropriate immunotherapy-based strategies for first-line treatment of advanced unresectable HCC.
• Demonstrate greater confidence in their ability to differentiate the benefits of immunotherapy-based combination regimens for first-line treatment of advanced unresectable HCC.

Available Beginning: December 13, 2024

Approximate Time to Complete: 30 minutes

CE Credits: 0.50 AMA PRA Category 1 Credit™/ABIM MOC points; available through 12/13/2025, 11:59 PM EST

Developed through a partnership between SITC and Medscape.